The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000552.5(VWF):c.4541T>G (p.Phe1514Cys)

CA114154

304 (ClinVar)

Gene: VWF (HGNC:7450)
Condition: von Willebrand disease type 2A (MONDO:0015628)
Inheritance Mode: Autosomal dominant inheritance
UUID: c90dcedf-05f4-4c7d-883e-1b316a64d157
Approved on: 2025-12-02
Published on: 2025-12-02

HGVS expressions

NM_000552.5:c.4541T>G
NM_000552.5(VWF):c.4541T>G (p.Phe1514Cys)
NC_000012.12:g.6018877A>C
CM000674.2:g.6018877A>C
NC_000012.11:g.6128043A>C
CM000674.1:g.6128043A>C
NC_000012.10:g.5998304A>C
NG_009072.1:g.110794T>G
NG_009072.2:g.110794T>G
ENST00000261405.10:c.4541T>G
ENST00000261405.9:c.4541T>G
ENST00000538635.5:n.421-24943T>G
NM_000552.3:c.4541T>G
NM_000552.4:c.4541T>G
More

Likely Pathogenic

Met criteria codes 5
PS4_Supporting PM2_Supporting PP4_Moderate PP1 PP3
Not Met criteria codes 6
BS2 BS1 BP4 BP5 BA1 PM5

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
von Willebrand Disease VCEP
The NM_000552.5:c.4541T>G p.(Phe1514Cys) variant in VWF is a missense variant predicted to cause substitution of phenylalanine by cysteine at amino acid 1514. This variant is absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.93, which is above the ClinGen VWD VCEP threshold of >0.644 and predicts a damaging effect on VWF function (PP3). At least 1 proband with this variant displayed excessive mucocutaneous bleeding as well as laboratory phenotypes of very low VWF activity (measured by VWF:RCo), low activity/VWF:Ag ratio and loss of high molecular weight multimers, which together are highly specific for VWD type 2A. (PP4_moderate, PMID 8435341). The variant has been reported to segregate with VWD type 2A through >2 affected meioses from 1 family (PP1; PMID: 8435341). This variant has been reported in at least 1 additional proband with reduced VWF:Ag to activity ratio (PS4_supporting; PMID: 40393667). In summary, this variant meets the criteria to be classified as likely pathogenic for autosomal dominant von Willebrand disease Type 2A based on the ACMG/AMP criteria applied, as specified by the ClinGen VWD VCEP (v1): PP1, PP3, PP4_Moderate, PM2_Supporting, PS4_Supporting.
Met criteria codes
PS4_Supporting
This variant has been reported in at least 1 additional proband with reduced VWF:Ag to activity ratio (PS4_supporting; PMID: 40393667).
PM2_Supporting
This variant is absent from gnomAD v4.1.0 (PM2_Supporting).
PP4_Moderate
At least 1 proband with this variant displayed excessive mucocutaneous bleeding as well as laboratory phenotypes of very low VWF activity (measured by VWF:RCo), low activity/VWF:Ag ratio and loss of high molecular weight multimers, which together are highly specific for VWD type 2A. (PP4_moderate, PMID 8435341).
PP1
The variant has been reported to segregate with VWD type 2A through >2 affected meioses from 1 family (PP1; PMID: 8435341).
PP3
The computational predictor REVEL gives a score of 0.93, which is above the ClinGen VWD VCEP threshold of >0.644 and predicts a damaging effect on VWF function (PP3).
Not Met criteria codes
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5
Phe1514Ser has been reported in at least one type 2A patient (PMID: 40393667) but has not yet been classified by the VWD VCEP.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.